| Role |
Name |
Disclosure |
Details |
| Author | Joe Verghese, MD, MRCPI, Associate Professor, Department of Neurology, Albert Einstein College of Medicine | Nothing to disclose | Details | | Medical Editor | Rodrigo O Kuljis, MD, Esther Lichtenstein Professor of Psychiatry and Neurology, Director, Division of Cognitive and Behavioral Neurology, Department of Neurology, University of Miami School of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Richard J Caselli, MD, Professor, Department of Neurology, Mayo Medical School, Rochester, MN; Chair, Department of Neurology, Mayo Clinic of Scottsdale | Nothing to disclose | Details | | CME Editor | Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital | Nothing to disclose | Details | | Chief Editor | Howard A Crystal, MD, Professor, Departments of Neurology and Pathology, State University of New York Downstate; Consulting Staff, Department of Neurology, University Hospital and Kings County Hospital Center | Pfizer Myriad | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Rodrigo O Kuljis, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Richard J Caselli, Managing Editor |
The contributor discloses no conflict of interest. |
|